The unprecedented success of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib in myelofibrosis (MF) provided muchneeded impetus for clinical drug development for the Philadelphia chromosomeenegative myeloproliferative neoplasms. The survival benefit conferred by this agent, along with its marked efficacy with regard to spleen volume and symptom reduction, have made ruxolitinib the cornerstone of drug therapy in MF. However, there remain significant unmet needs in the treatment of patients with MF, and many novel classes of agents continue to be investigated in efforts to build on the progress made with ruxolitinib. These include inhibitors of histone deacetylases (HDACs) and DNA methyltransferases, phosphatidylinositol-3-kinase isoforms, heat shock protein 90, cyclin-dependent kinases 4/6, and Hedgehog signaling, among others. In parallel, other JAK inhibitors with potential for less myelosuppression or even improvement of anemia, greater selectivity for JAK1 or JAK2, and the ability to overcome JAK inhibitor persistence are in various stages of development. First-in-class agents such as the activin receptor IIA ligand trap sotatercept (for anemia of MF), the telomerase inhibitor imetelstat, and the antifibrotic agent PRM-151 (recombinant human pentraxin-2) are also in clinical trials. In polycythemia vera, a novel interferon administered every 2 weeks is being developed for front-line therapy in high-risk individuals, and inhibitors of human double minute 2 (HDM2) have shown promise in preclinical studies, as have HDAC inhibitors such as givinostat (both in the laboratory and in the clinic). Ruxolitinib is approved for second-line therapy of polycythemia vera and is being developed for essential thrombocythemia.
Introduction
The marked improvement in symptoms and reduction in splenomegaly among patients with intermediate-2 or high-risk myelofibrosis (MF) receiving ruxolitinib observed in the pivotal COMFORT I and II trials compared to placebo and best available therapy (BAT), respectively, led to the approval of this agent by the US Food and Drug Administration (FDA) in 2011 for the treatment of patients with intermediate-or high-risk MF. 1, 2 Additionally, an overall survival benefit of ruxolitinib treatment was observed in COMFORT I after a median follow-up of 12 months 1 ; in COMFORT II, this took a median of 3 years to emerge. 3 In both trials, extensive crossover occurred after the primary end point had been assessed; despite this, the survival advantage for patients originally randomized to ruxolitinib persisted after a median of 5 years of follow-up (median survival not reached vs. 4.1 years for BAT in COMFORT II). 4 The prolongation of survival with ruxolitinib in higher-risk patients with MF has also been seen in multiple retrospective comparisons 5, 6 as well as in a pooled analysis of the COMFORT trials. 7 Ruxolitinib's efficacy appears unaffected by mutational status, 8 although the number of mutations does seem to matter (lower rates of spleen response, shorter time to treatment discontinuation, and shorter overall survival in patients with ! 3 myeloid malignancy-associated mutations). 9 Spleen responses to ruxolitinib are dose dependent and correlate with survival. 5, 10 While the COMFORT trials specifically studied intermediate-2 and high-risk patients, substantial data exist to support the efficacy of ruxolitinib in intermediate-1 risk patients as well. 11, 12 The benefits of ruxolitinib observed in clinical trials have been recapitulated in real-life settings, including those of early initiation of treatment. 10 Accordingly, ruxolitinib is now being studied in highmolecular-risk patients without significant symptoms or splenomegaly in the placebo-controlled ReTHINK trial in Europe. 13 For the above reasons, ruxolitinib has evolved to become the standard of care for most patients with MF.
financial constraints. JAK2 status or allele burden had no impact on response (clinical or molecular), time to response, or duration of therapy. Median durations of hematologic and molecular responses were 66 and 53 months, respectively; complete molecular responses were the most durable. A total of 35% of patients discontinued therapy because of toxicity, and new, late (! 2 years from therapy initiation) treatment-emergent grade 3/4 toxicity was seen in 17%. Even among patients in complete hematologic remission (CHR), vascular adverse events (AEs) and disease transformation occurred in 5 patients each. 25 The Myeloproliferative Disorders Research Consortium (MPD-RC) recently reported the results from an interim analysis (n ¼ 75) of a global phase 3 trial of front-line pegylated IFN-a-2a compared with HU in high-risk patients with PV or ET. 26 The overall response rate (ORR) was not significantly different between the 2 arms: 69% for HU and 53% for pegylated IFN-a-2a (P ¼ .6). The percentages of patients with CHR (the primary end point) in the 2 arms were similar even when the analysis was broken down by diagnosis, and also when patients who never initiated treatment were excluded. The rate of phlebotomy use among the 38 patients with PV significantly favored pegylated IFN-a-2a, which was also clearly associated with higher rates of grade 3 toxicity. 26 Ropeginterferon alfa-2b is a next-generation monopegylated IFN-a-2b isoform with a longer elimination half-life, permitting administration every 2 weeks. 27 In a phase 1/2 study in 51 patients with PV, there were no dose-limiting toxicities, and the ORR was 90% (CHR in 47% and partial hematologic remission in 43%). The best molecular response was complete in 21% and partial in 47%. Responses did not correlate with dose. 27 On the basis of these findings, the PROUD-PV trial, a phase 3 randomized controlled trial (RCT) comparing this agent to HU in 257 patients with PV, was conducted. 28 Patients could be naive to cytoreduction or have previously received HU (cumulative exposure 3 years), but if the latter, they must not have been intolerant of HU or experienced complete response to it. This was a noninferiority trial with CHR as the primary end point. At 12 months, the rate of CHR in the ropeginterferon alfa group was 43.1% and in the HU group was 45.6%, demonstrating noninferiority (P ¼ .0028). When considering CHR with normalization of spleen length, the rates were 21.3% and 27.6%, respectively, but the median spleen length at baseline was near normal, and the observed change was not clinically relevant. Cytopenias were significantly more frequent with HU, as was nausea, while increased gamma glutamyl transferase was seen significantly more frequently in the ropeginterferon alfa arm. While not statistically significant, autoimmune, endocrine, psychiatric, and cardiovascular disorders were more common among patients receiving ropeginterferon alfa. 28 
Ruxolitinib
As noted above, ruxolitinib was approved in 2014 for HU-resistant/intolerant patients with PV on the basis of the results of the RESPONSE trial. 21 In this RCT, ruxolitinib proved statistically significantly superior to BAT in terms of the primary end point, which was a composite of hematocrit control through week 32 and a ! 35% spleen volume reduction (SVR), as well as each individual component of the primary end point, CHR rates, and the rate of ! 50% reduction in the myeloproliferative neoplasm (MPN) symptom assessment form (SAF) total symptom score (TSS) at week 32. 21 Of note, the majority of patients in the BAT arm received HU despite having previously shown evidence of resistance or intolerance to this agent, reflecting the lack of effective options for this population. The benefits of ruxolitinib were sustained after a minimum of 80 weeks of follow-up. 29 Most BAT patients crossed over to ruxolitinib at or soon after week 32. Among these patients, 79.2% did not require phlebotomy, and 18.8% experienced a ! 35% SVR after 32 weeks of treatment. Importantly, the rate of thromboembolic events was 1.8 per 100 patient-years among patients originally randomized to ruxolitinib versus 8.2 per 100 patient-years among patients originally randomized to BAT. 29 The mean percent change from baseline JAK2 V617F allele burden among the 104 patients randomized to ruxolitinib was À40% at week 208. 30 Because the pivotal RESPONSE trial required the presence of splenomegaly, a finding present in less than half of PV patients at diagnosis, 31 the very similarly designed phase 3B RESPONSE-2 RCT was subsequently conducted to assess the efficacy of
Developmental Therapeutics in MPN ruxolitinib versus BAT in HU-resistant/intolerant patients without palpable splenomegaly. 32 The primary end point, the proportion of patients with hematocrit control at week 28, occurred in 46 (62%) of 74 patients receiving ruxolitinib and 14 (19%) of 75 patients receiving BAT, which, again, was HU in 37 (49%) of 75 patients at randomization.
32
Ruxolitinib was also investigated for its symptom benefit in another phase 3B RCT, RELIEF, in patients with PV well controlled on HU in terms of hematologic parameters but with persistent PV-related symptoms. 33 Patients were randomized 1:1 to switch to ruxolitinib (n ¼ 54) or stay on HU (n ¼ 56), with crossover to ruxolitinib permitted after week 16. This trial missed its primary end point, a ! 50% improvement from baseline in the MPN-SAF TSS cytokine symptom cluster (the sum of tiredness, itching, muscle aches, night sweats, and sweats while awake) at week 16, although this was experienced by more patients in the ruxolitinib than in the HU continuation group (43.4% vs. 29.6%, P ¼ .139).
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NCT02962388 is an upcoming phase 2/3 trial in France that will compare ruxolitinib to BAT (either anagrelide or IFN-a) in high-risk patients with ET who meet the European LeukemiaNet criteria for resistance or intolerance to HU. 34 A similar trial is planned in the United States using anagrelide as the active comparator. Ruxo-BEAT (NCT02577926) is an ongoing phase 3 trial in Germany comparing ruxolitinib to BAT in patients with high-risk PV or ET. ET patients may be treatment naive or previously treated. PV patients cannot have received cytoreductive therapy for more than 6 weeks.
Histone Deacetylase (HDAC) Inhibitors
HDAC inhibitors are pleiotropic agents that have multiple potential mechanisms of action in MPN cells, prominent among them being down-regulation of JAK2 via inhibition of the chaperone protein function of heat shock protein 90 (HSP90). 35 Givinostat and vorinostat are clearly active in patients with PV and ET, producing both spleen and hematologic responses in a substantial proportion of patients, apparently without regard to the mutational status of JAK2. [36] [37] [38] In these trials, reduction of the allele burden of mutated JAK2 was modest, and the drugs were particularly effective for pruritus. Fatigue and gastrointestinal AEs were significant concerns. [36] [37] [38] Nevertheless, givinostat continues to be developed for PV, with a 100% ORR among evaluable patients with active/uncontrolled disease noted after 3 cycles in an ongoing phase 1B/2 trial. 39 "Active/uncontrolled" was defined in this study as hematocrit ! 45% (or < 45% because of phlebotomy), platelets > 400 Â 10 9 /L, and leukocytes > 10 Â 10 9 /L. 39 
Human Double Minute 2 (HDM2) Inhibitors
HDM2 is an important negative regulator of p53 (promotes degradation of p53), and small-molecule inhibitors of HDM2 can trigger apoptosis in cells with intact p53 function by activating p53. Because IFN-a targets JAK2 V617Fþ progenitors in PV through activation of mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) 1, thereby increasing p53 transcription, 40 the combination of IFN-a with HDM2 inhibitors, which prevent the degradation of p53, provides an opportunity to induce p53-dependent apoptosis through disparate mechanisms. Indeed, combination treatment with subtherapeutic doses of pegylated IFN-a-2a and the HDM2 antagonist Nutlin-3 triggered increased apoptosis in PV CD34 þ cells and inhibited proliferation of these cells to a greater extent than normal CD34 þ cells. 41 The combination also reduced the proportion of JAK2 V617Fþ progenitors in 6 PV patients studied. 41 42 The clinical candidate HDM2 inhibitor idasanutlin is currently being studied in a phase 1 trial in patients with PV or ET (NCT02407080), with a provision for adding pegylated IFN-a-2a in subjects without at least a partial remission (PR) after 3 cycles. Of note, HDM2 inhibitors can cause significant thrombocytopenia by promoting p53-mediated apoptosis of megakaryocyte progenitors. 43 
BCL-2 Homology Domain 3 (BH3) Mimetics
BH3-mimetic drugs such as navitoclax and venetoclax bind to the BH3-binding groove of antiapoptotic proteins of the BCL-2 family, thereby displacing proapoptotic BH3-only proteins, which then trigger apoptosis through the mitochondrial pathway by activating the apoptosis effectors Bax and Bak. 44 Despite promising activity in a number of different tumor types, 45-48 the development of navitoclax was halted because of dose-limiting thrombocytopenia, an on-target effect resulting from inhibition of BCL-xL. 49 Similar to the preclinical data with the combination of HDM2 inhibitors and pegylated IFN-a discussed above, the combination of IFN-a and the BCL-2/-xL antagonist ABT-737 has also been shown to specifically target JAK2 V617Fþ hematopoietic progenitor cells in PV. 50 Synergism between JAK2 inhibitors and ABT-737 has also been demonstrated in JAK2 V617F -driven MPN cells as a means of overcoming ruxolitinib resistance. It is possible that agents such as idasanutlin and navitoclax will find a place in therapy of MPN such as PV and ET, where thrombocytopenia is less likely to be a problem in the clinical setting.
Developmental Therapeutics in MF New Agents for Anemia
Anemia, present in w30% of patients with MF at diagnosis and developing in essentially all patients at some point in their disease course, is difficult to treat. 51 No agent is specifically approved for this indication, and anemia is worsened, particularly early in therapy, by ruxolitinib, although anemia related to ruxolitinib does not carry the same adverse prognosis as disease-related anemia. 52 Response rates in real-world settings to currently available agents such as danazol, erythroid-stimulating agents, and immunomodulatory drugs such as thalidomide or lenalidomide are in the 20% to 30% range. Furthermore, lenalidomide is difficult to combine with ruxolitinib because of additive myelosuppressive effects. 53 Pomalidomide appeared highly promising in a single-arm phase 2 trial, transfusion-dependent (TD) patients with MF yielded the exact same rate of transfusion independence (TI) in both arms (16%). 55 Sotatercept is a first-in-class fusion protein consisting of the extracellular domain of activin receptor type IIA conjugated to the Fc fragment of human IgG1 that traps ligands of the transforming growth factor beta superfamily such as growth and differentiation factor 11 (GDF11) secreted by BM stromal cells, and in doing so relieves their blockade of terminal erythropoiesis. 56, 57 In preclinical models of b-thalassemia, sotatercept corrects ineffective erythropoiesis and improves anemia. 58 RAP-011, a murinized ortholog of sotatercept, has similar effects in hepcidin transgenic mice 59 and in a zebrafish model of Diamond-Blackfan anemia. 60 Sotatercept displayed promising evidence of clinical activity (40% rate of hematologic improvement in the erythroid lineage HI-E) in a cohort (n ¼ 53) of mostly high-transfusion-burden, erythroid-stimulatingagenterefractory patients with lower risk myelodysplastic syndrome or chronic myelomonocytic leukemia and was well tolerated. 61 Early results from an ongoing phase 2 study of sotatercept in patients with MF and anemia were recently presented. 62 Responses, including TI as defined by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT), 63 were noted in 5 (36%) of 14 evaluable patients. A separate cohort investigating the addition of sotatercept in anemic patients on a stable dose of ruxolitinib has now been added to this trial (NCT01712308). 62 
Newer JAK Inhibitors
Although a number of JAK inhibitors have been investigated in clinical trials over the years, only a few remain in clinical development, and ruxolitinib is the only one approved for MPN, most of the others having been discontinued due to toxicity.
Pacritinib. Pacritinib is a JAK2-selective inhibitor (it does not inhibit JAK1) that also inhibits fms-like tyrosine kinase 3 (FLT3), colony-stimulating factor 1 receptor (CSF1R), and interleukin-1 receptoreassociated kinase 1 (IRAK1) at nanomolar concentrations. 64 In a phase 2 study in MF patients (n ¼ 35, 26 evaluable) that allowed any degree of cytopenia, it produced a 31% rate of SVR (! 35%, by magnetic resonance imaging [MRI] ) and a ! 50% reduction in palpable spleen length in 42% of subjects from baseline up to week 24; median MF symptom improvement was ! 50% for all symptoms except fatigue. 65 Symptom responses were durable, and a ! 50% reduction in TSS from baseline was observed in 15 (48.4%) of 31 patients up to week 24; this increased to 18 (58.1%) of 31 patients up to the last visit on treatment, with the 3 additional responses occurring at week 36. Grade 1/2 gastrointestinal toxicities, anemia, and thrombocytopenia were the most common AEs. Nine patients (26%) discontinued due to AEs. This trial was prematurely terminated by the sponsor for commercial reasons, which affected 8 patients (23%) still receiving therapy. 65 The overall results with pacritinib were similar in another phase 1/2 trial, in which 31 patients with MF and any degree of cytopenias received pacritinib, 400 mg daily, in the phase 2 portion. 66 The primary end point of ! 35% SVR by MRI was reached in 4 (23.5%) of 17 evaluable patients at week 24, although a much higher proportion (47.4%) of evaluable patients experienced ! 50% spleen length reduction by palpation. Seven (38.9%) of 18 evaluable patients experienced a ! 50% decrease in symptom score at week 24.
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On the basis of these encouraging results, pacritinib was evaluated in 2 phase 3 trials, PERSIST-1 and PERSIST-2. PERSIST-1 compared pacritinib (400 mg daily) to BAT 2:1 in 327 JAK inhibitor-naive patients with intermediate-or high-risk MF, absolute neutrophil count > 0.5 Â 10 9 /L, palpable splenomegaly ! 5 cm, and a MPN-SAF TSS ! 13. 67 BAT could not include ruxolitinib. A total of 32% and 15% of patients, respectively, had platelet counts < 100 Â 10 9 /L and < 50 Â 10 9 /L. The ! 35% SVR (primary end point) rates in the intention-to-treat (ITT) analysis were 19.1% for pacritinib and 4.7% for BAT at week 24 (P ¼ .0003). By ITT analysis, 24.5% of pacritinib-treated patients versus 6.5% of BAT-treated patients experienced ! 50% improvement in the TSS (P < .0001). The superior efficacy of pacritinib over BAT was preserved among the patients with baseline platelets < 100 Â 10 9 /L and < 50 Â 10 9 /L. Among erythrocyte-TD patients, 25.7% of patients in the pacritinib arm experienced TI, as opposed to no patients in the BAT arm (P ¼ .043). 67 At week 60, 24% of evaluable pacritinib-treated patients experienced SVR ! 35%. 68 Crossover from BAT to pacritinib was permitted after week 24 or earlier in the event of disease progression. Ninety (84%) of 107 patients crossed over from BAT to pacritinib; 19% of evaluable crossover patients experienced ! 35% SVR at week 36 after crossover. Treatment-emergent diarrhea with pacritinib was most common during the first 8 weeks of treatment (all grades, 51%; grade 3/4, 2.7%). Cytopenias were more common with pacritinib versus BAT, while peripheral neuropathy (PN) occurred more frequently in BAT-treated patients. 68 In contrast to PERSIST-1, PERSIST-2 was conducted exclusively in patients with platelets 100 Â 10 9 /L, a recognized adverse prognostic feature in MF, 69 and both prior JAK inhibitor use and use of ruxolitinib in the BAT arm were allowed. 70 Patients were randomized 1:1:1 to pacritinib 200 mg twice daily, 400 mg once daily, or BAT. The percentages of patients experiencing ! 35% SVR by imaging and ! 50% reduction in TSS, both from baseline to week 24, were coeprimary end points. Thirty-two BAT patients (44%) in the ITT efficacy population received ruxolitinib at some point during the study. Pacritinib (pooled data) was significantly more effective at inducing a ! 35% SVR than BAT (18% vs. 3%, P ¼ .001), and 25% of pacritinib patients experienced a ! 50% reduction in their TSS compared to 14% of BAT patients (P ¼ .079). Considering the 2 pacritinib dose cohorts individually, pacritinib 200 mg twice daily was significantly better than BAT on both counts (SVR and TSS), while pacritinib 400 mg once daily beat BAT in terms of SVR but not in terms of TSS improvement. Erythrocyte-TD improved by week 24 in more patients receiving pacritinib than patients receiving BAT. Treatment-emergent AEs for pacritinib were as expected (gastrointestinal and hematologic) and were generally less frequent for twice-daily as compared to oncedaily administration. The former also experienced higher steadystate plasma levels but lower peak concentrations. 73 In the dose expansion phase of this study, subjects received either 150 or 300 mg once daily, or 150 mg twice daily for 9 months. The spleen response rate was 39% (57 of 148 evaluable patients), and the anemia response rate (composite of TI rate among erythrocyte-TD patients and rate of hemoglobin improvement in transfusion-independent, anemic patients) was 53% (59 of 111 patients). The median duration of spleen response was 324 days, and the median durations of 12-week TI and anemia response (in transfusion-independent patients) had not been reached at the time of presentation. Of note, spleen responses in this study were determined by palpation, and baseline transfusion dependence was loosely defined. Grade 3/4 thrombocytopenia and neutropenia related to momelotinib occurred in 29% and 5%, respectively, and grade 1/2 PN was reported by 38% of patients. 73 Data on 100 patients from the above study enrolled at the Mayo Clinic (Rochester, MN) were published separately, 74 and this sponsor-independent analysis was recently updated (median followup 3.2 years). 75 Of these 100 patients, 63%, 36%, and 1% had high-risk, intermediate-2, and intermediate-1 disease, respectively; 49% were erythrocyte-TD, 50% had an abnormal karyotype, and 21% had previously received another JAK inhibitor. After a median treatment duration of 1.7 years, momelotinib-related grade 3/4 AEs included thrombocytopenia (34%), neutropenia (9%), anemia (5%), elevated lipase (7%), liver enzyme abnormalities (2%-4%), and headache (2%). Grade 1/2 PN occurred in 47% of patients. Momelotinib treatment-emergent PN tends not to be reversible. 76 Clinical improvement 63 was noted in 57%, anemia responses in 44%, and spleen response in 43% of patients. A total of 51% of erythrocyte-TD patients experienced TI. MF-related symptoms improved markedly in most subjects. 75 Twice-daily administration of momelotinib was evaluated in a separate phase 1/2 study in 61 patients with intermediate-or highrisk MF. 77 The dose chosen for expansion in the phase 2 portion was 200 mg twice daily. Diarrhea (45.9%), PN (44.3%), thrombocytopenia (39.3%), and dizziness (36.1%) were the most common AEs. Using the 2006 IWG-MRT criteria for response assessment, 78 the spleen response rate (by palpation) was 72% and the anemia response rate 45% (among evaluable subjects). One patient experienced a PR, and 56.7% had clinical improvement. By MRI, the spleen response rate was 54% among subjects with palpable splenomegaly at baseline. Fifteen (51.7%) of 29 erythrocyte-TD subjects experienced 8-week TI, but on applying the newer, more stringent criteria for transfusion dependence and independence, 63 4 (21.1%) of 19 of subjects experienced (12-week) TI. MF symptoms improved in most subjects, and the median reduction in the JAK2 V617F allele burden was 21.1% at 24 weeks. 77 Momelotinib has been compared head to head with ruxolitinib in a phase 3 RCT in patients (n ¼ 432) with JAK inhibitor-naive MF (SIMPLIFY-1) and with BAT (2:1) in a phase 3 RCT in patients (n ¼ 156) previously treated with, but not refractory to, ruxolitinib (SIMPLIFY-2). The primary end point in both studies was the proportion of patients with a ! 35% SVR (by imaging) at week 24. Secondary end points included the proportion of patients with a ! 50% reduction in their MPN-SAF TSS and the proportion with TI at week 24. At the time of this writing, publicly available information on the results of these trials is limited to a press release from the company. 79 SIMPLIFY-1 was a noninferiority study, and while noninferiority of momelotinib to ruxolitinib occurred in terms of ! 35% SVR at week 24 (momelotinib 26.5%, ruxolitinib 29%), this did not occur in terms of symptomatic benefit. Expectedly, momelotinib performed better than ruxolitinib with respect to anemia-related end points, but formal statistical testing was not undertaken for these. In SIMPLIFY-2, most (88%) BAT-treated patients continued to receive ruxolitinib. The trial did not meet its primary end point of superiority of momelotinib in terms of ! 35% SVR at week 24. Momelotinib outperformed BAT in terms of TSS improvement and achievement of TI, but formal statistical testing was not undertaken. How momelotinib might improve anemia despite inhibiting JAK1/2 is not well understood, and one putative mechanism is inhibition of ALK2-mediated hepcidin expression in the liver, which in turn results in increased release of storage iron and promotion of erythropoiesis. 80 NCT02515630 is a phase 2 study investigating momelotinib in erythrocyte-TD patients with MF that examines changes in pharmacodynamic biomarkers and markers of anemia in addition to clinical end points.
NS-018. NS-018 is a JAK2-selective inhibitor with a drug concentration causing 50% inhibition of < 1 nM and 30-to 50-fold greater selectivity for JAK2 than for other JAK family kinases (JAK1, JAK3, TYK2) that also inhibits Src-family kinases. 81 NS-018 potently kills cell lines expressing constitutively activated JAK2, suppresses endogenous erythroid colony formation by primary cells from PV patients and reduces leukocytosis and splenomegaly, improves BM fibrosis, and prolongs survival in a mouse model of JAK2 V617F -driven MF without causing peripheral anemia or thrombocytopenia. 81, 82 Forty-eight patients with MF, 23 (48%) of whom had previously been treated with a JAK inhibitor, received NS-018 in a phase 1 trial. 83 The most frequent drug-related AEs were thrombocytopenia (27%), anemia (15%), dizziness (23%), and nausea (19%). The recommended phase 2 dose (RP2D) was 300 mg daily. Fifty-six percent of patients (47% of those who had previously received a JAK inhibitor) experienced a ! 50% reduction in palpable spleen size, and improvements in MF-related symptoms were noted. Eleven (37%) of 30 evaluable patients had improvement in BM fibrosis from baseline after 3 cycles, although the mutant JAK2 allele burden did not change significantly. CHZ868. JAK2 inhibitor persistence is a phenomenon in which JAK-STAT signaling can be reactivated via heterodimerization between activated JAK2 and JAK1 or TYK2 despite continued therapy with a JAK2 inhibitor. 86 In fact, JAK2 inhibitor withdrawal is associated with resensitization to JAK2 inhibitors in this setting. However, this phenomenon of persistence appears restricted to type I JAK2 inhibitors, which bind the kinase in its active conformation. 87 CHZ868 is a type II JAK inhibitor, which binds to and stabilizes the inactive conformation of the kinase. 88 In preclinical studies, this agent was effective against JAK2-and MPL-mutant cell lines, including those exhibiting type I JAK inhibitor persistence. CHZ868 was also active in vivo, inducing greater reductions in the allele burden of mutant JAK2 in murine models than typically seen with type I JAK inhibitors.
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Imetelstat. The telomerase inhibitor imetelstat generated substantial interest when a pilot study in 33 patients with intermediate-2 or high-risk MF, 48% of whom had received prior JAK inhibitor therapy, reported complete remission (CR) or PR in 7 patients (21%) that lasted between 7 and 20þ months (median for PRs 10 months and for CRs 18 months). 89 Furthermore, BM fibrosis was reversed in all 4 patients with CR, and 3 of these patients had a molecular response. Responses did not, however, correlate with baseline telomere length. At the dose and schedule used in this study (9.4 mg/kg intravenously every 1-3 weeks), imetelstat was quite toxic, with high rates of myelosuppression (grade 3 anemia in 30% and grade 4 neutropenia and thrombocytopenia in 12% and 18% of patients, respectively). Grade 1/2 increases in bilirubin (12%), alkaline phosphatase (21%), and aspartate aminotransferase (27%) were frequent as well. 89 On the basis of these data, the IMbark trial (NCT02426086) was designed as a phase 2 study evaluating 4.7 or 9.4 mg/kg of imetelstat administered intravenously every 3 weeks in approximately 200 patients with intermediate-2/high-risk MF that failed to respond to prior JAK inhibitor therapy. After a planned internal interim review at the 12-week time point, the sponsor decided to close the 4.7 mg/kg dosing arm as a result of insufficient activity. 90 For the 9.4 mg/kg dosing arm, it was decided to suspend new patient enrollment while continuing to treat existing patients, with plans for a second internal data review at 24 weeks, at which point further decisions regarding continued development of this agent for MF will be taken. 90 PRM-151. PRM-151 is recombinant pentraxin 2 (serum amyloid P), a highly phylogenetically conserved circulating plasma protein and soluble pattern recognition receptor of the innate immune system that may localize to sites of injury to aid in removal of damaged tissue. 91 It is currently in clinical development for the treatment of various fibrotic diseases. In an open-label, adaptive trial, PRM-151 was administered at a dose of 10 mg/kg intravenously weekly or every 4 weeks, with or without ruxolitinib, for 24 weeks to patients with intermediate-or high-risk MF and grade 2 or higher BM fibrosis. 92 At study entry, patients could either be receiving no therapy or receiving a stable (for ! 12 weeks) dose of ruxolitinib.
There was no restriction with regard to platelet count, and splenomegaly was not required. Twenty-two percent of patients were JAK inhibitor naive, and 52% had received prior JAK inhibitor therapy, not including patients receiving ruxolitinib at the time of enrollment. The ORR was 35% (9 of 26), with at least one response in each arm. Four patients had clinical improvement in symptoms, and 6 had BM fibrosis responses (1 patient had both). PRM-151 was very well tolerated. 92 Patients deriving clinical benefit were permitted to continue PRM-151 beyond week 24, and results of 13 patients who had completed 72 weeks of therapy were presented. 93 Thirty-one percent were JAK inhibitor naive, and 69% had either received a JAK inhibitor in the past or were receiving ruxolitinib at study entry. A total of 54% of patients had a morphologic response in their BM, and 85% had a response by computer-assisted image analysis. Three of 5 patients who were receiving red blood cell transfusions at baseline experienced TI, as did all 4 patients who were receiving platelet transfusions at baseline. Two of 9 patients with palpable splenomegaly at baseline experienced a ! 50% reduction lasting > 12 weeks. The TSS improved from baseline by ! 50% and 100% between 24 and 72 weeks in 69% and 38% of patients, respectively.
93 LCL-161. Preclinical studies reveal a central role for tumor necrosis factor alpha (TNF-a) in promoting clonal dominance of JAK2V617F-expressing cells in MPN.
94 JAK2V617F appears to confer TNF-a resistance to a preneoplastic TNF-aesensitive cell while creating a TNF-aerich environment. 94 Second mitochondrial activator of caspases (Smac) mimetics are novel apoptosisinducing agents that stimulate the ubiquitinylation and proteasomal degradation of cellular inhibitors of apoptosis, 95 proteins that play an important role in tumor cell resistance to cytotoxicity mediated by TNF superfamily cytokines. 96 These agents have been shown to sensitize cancer cells to TNF familyeinduced apoptosis. 96 Results from a phase 2 trial of the Smac-mimetic LCL-161 in 21 patients with intermediate-or high-risk MF who were intolerant to, ineligible for, or relapsed/refractory to JAK inhibitors were recently presented. 97 There were no eligibility cutoffs for spleen size or blood counts. Most patients (81%) had received ! 2 prior therapies, and two-thirds had received a JAK inhibitor in the past. Six (38%) of 16 evaluable patients had 9 objective responses, all of which were clinical improvements except one, which was a cytogenetic remission. Fatigue was the most prominent AE. 104, 105 and pracinostat 106 have been studied as single agents in MF.
Although panobinostat was better tolerated at a dose of 25 mg 3 times a week than 40 mg 3 times a week, discontinuation was still frequent because of perceived therapy ineffectiveness. 104, 105 Compounding the issue of chronic toxicities such as fatigue, diarrhea, and thrombocytopenia is the fact that the disease-modifying effects of HDAC inhibitors in MF take a long time to emerge. 105, 107 Both panobinostat and pracinostat are being studied in combination with ruxolitinib in patients with MF (NCT01433445, NCT01693601, NCT02267278). The RP2Ds of panobinostat and ruxolitinib in combination were found to be 25 mg 3 times a week every other week for panobinostat and 15 mg twice daily of ruxolitinib. 108 Spleen responses (! 35% SVR) to the combination (57% and 39% at 24 and 48 weeks, respectively) were higher than seen with ruxolitinib alone in the COMFORT trials, without overt increases in toxicity. 108 Combinations With Hypomethylating Agents. Abnormalities of methylation are common in MPN, 109 and JAK2 has a number of noncanonical actions that profoundly affect epigenetic processes. 119 In the expansion phase at week 24, 5 (45%) of 11 JAK inhibitor-naive patients and 2 (18%) of 11 patients previously treated with JAK inhibitors experienced a ! 35% SVR from baseline. 119 While buparlisib is a pan-PI3K inhibitor, ruxolitinib is also being studied in combination with inhibitors of the delta isoform of PI3K (NCT02493530, NCT02718300). Preliminary results from a phase 1 trial of ruxolitinib and the next-generation PI3K delta inhibitor TGR-1202 were recently presented. 120 These findings formed the basis of a phase 1B/2 study (NCT01787552) of this drug combination in intermediate-to high-risk patients (n ¼ 27) with MF and palpable splenomegaly who had not previously received a JAK or HH inhibitor. 123 The
RP2Ds were determined to be 20 mg twice daily of ruxolitinib and 400 mg once daily of sonidegib. At 24 weeks, 12 patients (44.4%) experienced a ! 35% SVR by imaging. 123 The currently licensed (for advanced basal-cell carcinoma) HH (smoothened) inhibitor vismodegib is also being studied in combination with ruxolitinib in JAK/HH inhibitor-naive patients with intermediate-to high-risk MF and palpable splenomegaly ! 5 cm in a placebo-controlled trial (NCT02593760).
Combinations With Cyclin-dependent Kinase (CDK) Inhibitors. The CDKs are serine/threonine kinases that, together with the cyclins, serve as the engines of the cell cycle. In recent years, CDK4/ 6 have emerged as important targets for cancer therapy, and mechanistically, their combination with JAK inhibitors has been proposed as a potentially synergistic one.
124 JAK2 V617F promotes myeloproliferation by translationally up-regulating CDC25A, a phosphatase that serves as a key regulator of the G1/S cell cycle checkpoint 125 and down-regulating p27, an endogenous CDK inhibitor. 126 The combination of ruxolitinib and the CDK4/6 inhibitor ribociclib was recently shown to be synergistic in a JAK2 V617F xenograft model. 127 The triple combination of ruxolitinib, ribociclib, and PIM447, a PIM kinase inhibitor (PIM kinases activate D-type cyclins) was found to be even more effective in vivo, findings that were confirmed (with no additive toxicity) in a MPL W515L mouse model that most closely recapitulates human ET/ MF. 127 On the basis of these findings, a phase 1 trial of these 3 agents in combination is underway in patients with JAK2 V617F MF with splenomegaly ! 5 cm by MRI and adequate BM function (NCT02370706).
Conclusion
Although ruxolitinib remains the only approved therapy for MF today, efforts are ongoing on multiple fronts to identify rational combination partners for ruxolitinib on the basis of translational studies so as to further modify the natural history of this difficult disease. In parallel, the search continues for agents that might effectively combat the anemia of MF, thereby allowing dose optimization of ruxolitinib. While none of these agents is close to regulatory approval, several are promising, as we outline here. However, the experience with a number of different JAK inhibitors, many of which were discontinued as a result of toxicity concerns, tells a cautionary tale, particularly in light of recent information on pacritinib and momelotinib. Drug development in PV and ET poses different challenges, given the prolonged survival associated with these conditions. In the near future, we hope that ropeginterferon alfa-2b and ruxolitinib will be important new additions to the therapeutic armamentarium for PV and ET, respectively.
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